Clinical Trials Logo

Clinical Trial Summary

The usual standard of care for patients over 65 diagnosed with glioblastoma ("GBM") or Grade 4 astrocytoma, IDH-mutant is a 3-week course of radiotherapy, with concurrent and adjuvant temozolomide (TMZ). This radiation dose and length of treatment are less than what would be given for younger patients, primarily due to unclear survival benefits from randomized trials. However, survival remains dismal, and may be partially due to the reduced radiation dose. Recent studies investigating this have found that increased radiation dose (to the equivalent of what is normally given over 6 weeks in younger patients) over 3 weeks is well-tolerated and has improved survival rates. Additionally, with the advent of novel technology such as the MR-Linac, adaptive radiotherapy with this regimen using reduced radiation margins is possible. Use of the MR-Linac allows for daily MRI scans to be done prior to treatment, so plans can be adapted to tumour dynamics and anatomical deformations. In this trial, we will examine the outcomes of increased radiation dose, combined with reduced-margin adaptive radiotherapy in this patient population.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05565521
Study type Interventional
Source Sunnybrook Health Sciences Centre
Contact Chia-Lin (Eric) Tseng, MD
Phone 416-480-6100
Email chia-lin.tseng@sunnybrook.ca
Status Recruiting
Phase Phase 2
Start date December 13, 2022
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04762069 - A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Phase 2
Recruiting NCT04869449 - Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas Early Phase 1
Withdrawn NCT03480867 - Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA) Phase 1
Not yet recruiting NCT05653622 - Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma Phase 2
Recruiting NCT05954858 - Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma N/A
Recruiting NCT05052957 - hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) Phase 2
Recruiting NCT05977738 - Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin Early Phase 1
Recruiting NCT04614909 - Study of Pamiparib in Newly Diagnosed and rGBM Early Phase 1
Recruiting NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Recruiting NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Recruiting NCT06146738 - The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Recruiting NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Recruiting NCT04825275 - Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial Early Phase 1
Recruiting NCT05333588 - The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. Early Phase 1
Completed NCT05671016 - Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy
Recruiting NCT05271240 - Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM Phase 3
Recruiting NCT04469699 - Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma Phase 2
Recruiting NCT05720078 - UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) N/A